A review of hepatitis c virus (HCV) and the current management of genotype 1 chronic HCV infection
DOI:
https://doi.org/10.60787/tnhj.v12i4.142Keywords:
Hepatitis C genotype 1, Pegylated Interferon (Peg IFN), Protease inhibitors (PI), Telaprevir (TVR), Boceprevir (BOC), Ribavirin(RBV).Abstract
Background: Chronic Hepatitis C virus (HCV) is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end- stage liver disease. The addition of protease inhibitor with peginterferon alfa and ribavirin (triple therapy) for genotype 1 infected patients, are the current standard of care.
Method: Data was sourced from available journals and internet based search using pubmed, medline and google search.
Results: successful Treatment of Genotype 1 HCV infected patients with protease inhibitor based triple therapy has improved sustained virologic response (SVR) rates and treatment induced clearance of HCV infection.
Conclusion: significant progress in the management of chronic hepatitis C genotype 1 with the introduction of protease inhibitor (PI) in 2011 with peginterferon and ribavirin has optimized sustained virologic response (SVR).
Downloads
References
Lauer GM, walker BD. Hepatitis C virus infection. N Eng1 J Med 2001; 345: 41-52.
Kanwai F, Hoang T, kramer JR. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140:1182-1188.
Backus Li, Boothroyd DB, Phillips BR. A sustained virologic response reduces risk of all-cause mortality is patients with hepatitics C. clin gastroerterol Hepatol 2011; 9:509 – 516.
Morgan TR, Ghany MG, Kim HY. Outcome of sustained virnogical responders with histologically advanced chronic hepatitic C. Hepatrology 2010; 52:833-44.
George SL, Bacon BR, Brunt EM, Clinical virologic,histologic,andbiochemicaloutcomes after successful HCV therapy: a 5 year follow up of 150 patients. Hepatology 2009; 49:729-38.
Poordad F, McCone J Jr, Bacon BR, Brumo S, Manns MP, Sulkowski MS, Jacobson. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
Jacobson IM, McHutchison JG, Dusheiko G. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
Zeuzem S, Androne, P, Pol S. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
World Health Organization. Hepatitis C. WHO fact sheet No. 164 what year.
Alter MG, Kruszon-Moran D, Naina OV. the prevalence of hepatitis C virus infection in the United States. 1988 through 1994. N Eng1 J Med 1999; 341; 556 – 562.
Centre for disease control and prevent. Recommendationforpreventionandcontrol of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47 (No. RR-19): 1-39.
Olubuyide I O, Aliyu MB, Olaleye OA. Hepatitis B and C virus and hepatecellular carcinoma. Trans R Soc Trop Med Hyg 1997; 9;38-41.
Obienu O, Nwokediuko S, Malu A, Lesi OA GastroenterolResPract2011;2011:939673.
Multimer Dj. Olomu A, Skidmore S viral hepatitis in Nigeria sickle cell disease and blood donors. QJM 1994; 87:407-411.
Olokoba AB, Acama LA, Gashau W, Salawi FK. Trop Doct. 2011 Jul; 41(3): 146-7
Nelson PK, Mathers BM, Cowie B. Global Epidemiology of hepatitis B and hepatitis C in people who inject drugs: result of systematic reviews. Lancet 2011; 378:571-16.
William I. Epidemiology of hepatitis C in the United States. Am J Med 1989; 107:2S-9S.
NIHconsensusprogram.NationalInstitutesofHealthConsensusdevelopment conference panel statement: management of hepatitis C. Hepatology 1997; 26:2S-10S.
Poynard T, Bedossa P, Opolon P. Natural historyofliverfibrosisMETAVIR,CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
The VA Hepatitis C Resources Center program and National Hepatitis C program office VHA. Management of Psychiatric and substance use disorders in patients with Hepatitis C: A Reference for hepatitis C care providers 2005, pp 1-36.
HOSB,GroesslE,DollarhideA.Management of chronic hepatitis C in vaterans: the potential of integrated care model. Am J Gastroenterol 2008:103; 1810-23.
Dienstag JL. The role of liver biopsy in chronic hepatitis C. hepatology 2002; 36: S152 – 60.
McHutchison JG, lawits EJ, Shiffman ML, Muir AJ, Galler GW, Mccone J, et al. peginterferon alfa-2b or alfa 2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.
Manns MP, McHutchison JG, Gordon SC. Peginterferonalfa-2bplusribavirincompared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965.
Jacobson IM, McHutchison JG, Dusheiko GM,etal.TelaprevirforpreviouslyuntreatedchronichepatitisCvirusinfection. N Engl J Med. 2011;364:2405 – 2416.
Bacon Br, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
FriedMW, ShiffmanML, Reddy KR. Peginterferon alfa-21 plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
Sulkowksi MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in hemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11(3): 243 – 250.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 The Nigerian Health Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
